| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/11/2002 | WO2001088159A3 Cd28 synthebody for the modulation of immune responses |
| 04/11/2002 | WO2001087824A3 7-substituted fused ring tetracycline compounds |
| 04/11/2002 | WO2001087342A3 Delivery devices for treatment of vascular disease |
| 04/11/2002 | WO2001085935A3 Endothelial differentiation gene 6-like g protein coupled receptor |
| 04/11/2002 | WO2001085671A3 Anthranyl amides and their use as medicaments |
| 04/11/2002 | WO2001085128A3 Skin protectant spray compositions |
| 04/11/2002 | WO2001085125A3 Skin preparation |
| 04/11/2002 | WO2001084962A3 Compositions containing folic acid and reduced folate |
| 04/11/2002 | WO2001083450A3 (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors |
| 04/11/2002 | WO2001083031A3 Topical composition for the treatment of psoriasis and related skin disorders |
| 04/11/2002 | WO2001082868A3 A medicinal aerosol formulation |
| 04/11/2002 | WO2001078680A3 Pharmaceutical compositions comprising fluvastatin |
| 04/11/2002 | WO2001077079A3 Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade |
| 04/11/2002 | WO2001076715A3 Method for the fractionation of oil and polar lipid-containing native raw materials |
| 04/11/2002 | WO2001076572A3 Use of compatible solutes as substances having free radical scavenging properties |
| 04/11/2002 | WO2001074898A8 Charged compounds comprising a nucleic acid binding moiety and uses therefor |
| 04/11/2002 | WO2001074856A3 Wnt-7b-like polypeptides and nucleic acids encoding same |
| 04/11/2002 | WO2001074307A3 Compositions and methods for treating hair loss using oximyl- and hydroxylamino- prostaglandins |
| 04/11/2002 | WO2001068069A3 Pharmaceutical composition comprising paracetamol |
| 04/11/2002 | WO2001066085A3 Micellar pharmaceutical compositions for buccal and pulmonary application |
| 04/11/2002 | WO2001064207A3 Methods of modulating cell-adhesion mediated drug resistance |
| 04/11/2002 | WO2001060844A3 Peptide and nucleic acid coding therefor for the detection, diagnosis and therapy of diseases of the nervous system |
| 04/11/2002 | WO2001060372A3 Use of xanthine derivatives for preparing a medicine for preventing and treating osteoporosis |
| 04/11/2002 | WO2001058240A3 Photodynamic therapy for treating conditions of the eye |
| 04/11/2002 | WO2001049278A3 Compounds and compositions for use in inhibiting endoparasitic fatty acid biosynthesis |
| 04/11/2002 | WO2001045678A3 Medicament, a method for its production and the use thereof |
| 04/11/2002 | WO2001039804A3 Gd3 synthesis inhibitors for treating neuropathological disorders |
| 04/11/2002 | WO2001039573A3 Novel use of lung surfactant for treating legionnaire's disease |
| 04/11/2002 | WO2001036374A3 Bis-basic compounds for use as tryptase inhibitors, method for producing the same and their use as medicaments |
| 04/11/2002 | WO2001032680A3 18-nor-steroids as selectively active estrogens |
| 04/11/2002 | WO2001028589A3 Shaped body comprising an amphiphilic outer phase and a lipophilic inner phase |
| 04/11/2002 | WO2001024782A3 Pharmaceutical agent for the treatment of cachexia and/or cardiogenic shock |
| 04/11/2002 | WO2001019797A3 HYDROXYALKANOYL AMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
| 04/11/2002 | WO2001000185A3 1,4-denzothiazepines to treat obesity related disorders |
| 04/11/2002 | WO2000058523A9 Glucocorticoid receptor agonist and decreased pp5 |
| 04/11/2002 | WO2000052210A3 Methods for targeting rna molecules |
| 04/11/2002 | WO2000047214A9 Anti-resorptive bone cements and allogeneic, autografic, and xenografic bone grafts |
| 04/11/2002 | WO2000045805A9 Methods of inhibiting the hgf-met-upa-plasmin network with geldanamycin derivates |
| 04/11/2002 | WO2000044334A3 Novel injectable muscle relaxant formulations |
| 04/11/2002 | WO2000038518A9 Efficient and stable (in vivo) gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors |
| 04/11/2002 | WO2000032181A9 Method for reducing free-radical induced injury |
| 04/11/2002 | WO2000012493A9 Thiazoline acid derivatives |
| 04/11/2002 | US20020042535 Therapeutic compounds and methods of use |
| 04/11/2002 | US20020042530 Compositions and methods for their preparation from lepidium |
| 04/11/2002 | US20020042517 Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| 04/11/2002 | US20020042515 Tetrahydroquinolines |
| 04/11/2002 | US20020042513 Therapeutic compounds |
| 04/11/2002 | US20020042512 Alpha-acyl- and alpha-heteroatom-substituted benzene acetamide glucokinase activators |
| 04/11/2002 | US20020042511 New derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them |
| 04/11/2002 | US20020042507 Process for preparation of 9,11-epoxy steroids and intermediates useful therein |
| 04/11/2002 | US20020042505 Novel human ion channel protein and polynucleotides encoding the same |
| 04/11/2002 | US20020042501 Antiproliferative and antitumor agents and angiogenesis inhibitors |
| 04/11/2002 | US20020042447 Mixture of unsaturated fatty acid and antioxidant |
| 04/11/2002 | US20020042446 Treatment of addiction and addiction-related behavior |
| 04/11/2002 | US20020042445 Use of branched-chain fatty acids and derivatives thereof for the treatment of pain |
| 04/11/2002 | US20020042444 Treatment of lipid metabolic disorders using 5-(1,2-dithiolan-3-yl) valeric acid (alpha-lipoic acid) or its physiologically compatible salts |
| 04/11/2002 | US20020042443 Estrogen agonist / antagonist metabolites |
| 04/11/2002 | US20020042442 Ureas and carbamates of N-Heterocyclic carboxylic acids and carboxylic acid isosteres |
| 04/11/2002 | US20020042441 N-substituted indoles useful in the treatment of diabetes |
| 04/11/2002 | US20020042438 Use of ergothioneine and/or its derivatives as an anti-glycation agent |
| 04/11/2002 | US20020042436 Cardiovascular disorders; using valsartan |
| 04/11/2002 | US20020042435 Cyclic AMP-specific phosphodiesterase inhibitors |
| 04/11/2002 | US20020042434 Pharmaceutical composition |
| 04/11/2002 | US20020042433 For promoting animal growth and improving feed utilization efficiency by an animal, and as antimicrobial component in animal feeds |
| 04/11/2002 | US20020042432 Synergistic mixtures |
| 04/11/2002 | US20020042431 Zwitterionic tachykinin receptor antagonists |
| 04/11/2002 | US20020042430 Novel esters of 1, 4-disubstituted piperidine derivatives |
| 04/11/2002 | US20020042427 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors |
| 04/11/2002 | US20020042426 Novel basic derivatives of benz[e] isoindol-1-ones and pyrrolo[3,4-c] quinolin-1ones with 5-HT3-antagonistic activity, their preparation and their therapeutic use |
| 04/11/2002 | US20020042425 Transdermal treatment with 5-alpha reductase inhibitors |
| 04/11/2002 | US20020042424 Viricides |
| 04/11/2002 | US20020042423 Methods for identifying compounds that bind to hla molecules and use of such compounds as hla-agonists or antagonists |
| 04/11/2002 | US20020042422 Certain pyrazole derivatives as corticotropin-releasing factor CRF1 ligands |
| 04/11/2002 | US20020042421 Antiinflammatory agents |
| 04/11/2002 | US20020042419 Administering growth hormone secretagogue |
| 04/11/2002 | US20020042418 Inhibition of matrix metalloproteases by substitued biaryl oxobutyric acides |
| 04/11/2002 | US20020042417 Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids |
| 04/11/2002 | US20020042416 6-azauracil derivatives as IL-5 inhibitors |
| 04/11/2002 | US20020042415 Dipeptide derivatives |
| 04/11/2002 | US20020042413 Central nervous system disorders; cognition activators |
| 04/11/2002 | US20020042412 Fused azepinone cyclin dependent kinase inhibitors |
| 04/11/2002 | US20020042411 Condensed thiophene compounds and pharmaceutical use thereof |
| 04/11/2002 | US20020042409 Thiophene derivatives useful as anticancer agents |
| 04/11/2002 | US20020042408 Antibiotic compounds |
| 04/11/2002 | US20020042407 Substituted porphyrins |
| 04/11/2002 | US20020042406 Ring opening metathesis of alkenes |
| 04/11/2002 | US20020042405 Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure |
| 04/11/2002 | US20020042404 Use for budesonide and formoterol |
| 04/11/2002 | US20020042403 Use of vitamin D analogs to treat conditions related to increased oxidative stress |
| 04/11/2002 | US20020042402 Method of using matrix metalloproteinase inhibitors in filtering blebs following glaucoma filtering surgery and in the treatment of ischemic damage to the retina and optic nerve |
| 04/11/2002 | US20020042401 Use of sex steroids function modulators to treat wounds and fibrotic disorders |
| 04/11/2002 | US20020042400 Antihistamines |
| 04/11/2002 | US20020042399 Analgesics; skin disorders |
| 04/11/2002 | US20020042397 4-hydroxycinnoline-3-carboxyamides as antiviral agents |
| 04/11/2002 | US20020042396 Amino acid derivatives |
| 04/11/2002 | US20020042395 Method of treating high plasma cholesterol levels |
| 04/11/2002 | US20020042392 Anticancer agents |
| 04/11/2002 | US20020042391 Anticancer agents; viricides |
| 04/11/2002 | US20020042390 Therapy for central nervous system disorders; administeringnucleoside |
| 04/11/2002 | US20020042387 Administering nucleic acid as antiinflammatory agent |